{"id":"sofenacin","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["Solfenacin 10 mg"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=sofenacin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:34:22.386524+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:34:43.766772+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:34:27.763716+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=sofenacin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:34:28.497533+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Sofenacin, developed by Mansoura University, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the university's research and development capabilities. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.","ecosystem":[],"_scrapedAt":"2026-03-28T00:08:38.883Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:34:43.766901+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03038321","phase":"PHASE4","title":"Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2017-02-01","conditions":"Non-Muscle-invasive Bladder Cancer (NMIBC), Bacillus Calmette-Guerin (BCG) Cystitis, Intra-vesical Instillation","enrollment":150}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"DRUG INEFFECTIVE"},{"count":3,"reaction":"FATIGUE"},{"count":3,"reaction":"URINARY INCONTINENCE"},{"count":2,"reaction":"ANGINA PECTORIS"},{"count":2,"reaction":"CONSTIPATION"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"GAIT DISTURBANCE"},{"count":2,"reaction":"INSOMNIA"},{"count":2,"reaction":"MEMORY IMPAIRMENT"},{"count":2,"reaction":"MOBILITY DECREASED"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"sofenacin","genericName":"sofenacin","companyName":"Mansoura University","companyId":"mansoura-university","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:34:43.766901+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}